BUSINESS

Astellas Records 22% Revenue Growth in 1H Riding on Strategic Assets

October 31, 2024

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Astellas has achieved a higher-than-expected growth in revenue of 22.0% over the year in the April-September stretch of FY2024, sparked by the expansion in sales of its key strategic products, according to its earnings results released on October 30. The…

To read the full story

Astellas Beats H1 Forecast on Strategic Product Growth, Cost Controls
October 31, 2025
Astellas Assembles Task Team to Assess US Tariff Risks
July 31, 2025
Astellas Gears Up for Xtandi Patent Cliff with Next-Gen Assets, Cost Cuts
April 28, 2025
Xtandi’s Global Sales Surge Nearly 30% in April-June: Astellas
August 2, 2024
Astellas’ FY2023 Operating Profit Tumbles 80% Due to Iveric Bio Buyout
April 26, 2024
Astellas Slashes FY2023 Profit Forecasts on Gene Therapy Impairment Loss
April 15, 2024
Astellas Slashes FY2023 Veozah Forecast as Vertical Start-Up Plan Stumbles
February 6, 2024
Astellas Squeaks Out Sales Rise as FX, Mainstay Growth Offset Generic Hit
November 2, 2023
Astellas’ Q1 Sales Skid on Lexiscan Generic Erosion, but Full-Year Growth Expected with Hot Flash Med
August 2, 2023
Astellas Logs 17.2% Sales Growth in FY2022 on Xtandi, but Profits Fall
April 28, 2023
Astellas’ April-December Sales Up 17% on FX Tailwind; Xtandi Slows in US but Brisk in Japan
February 7, 2023
Astellas’ Half-Year Revenue Up 17% on FX Boon; Xtandi US Sales Stall
November 2, 2022
Astellas’ Earnings Hit by FX as Cost Rate Worsens on Overseas Inventories
August 2, 2022
Astellas Logs 1st Sales Growth in 3 Years in FY2021; Chairman Hatanaka to Bow Out
April 28, 2022
Astellas to Write Off Massive Losses over AT132, DMD Gene Therapies
April 25, 2022
Astellas Sees Surge in 9-Month Revenue on Xtandi Growth, US Market Recovery
February 3, 2022
Astellas’ Half-Year Revenue Up Nearly 6% on Bullish Xtandi
November 1, 2021
Astellas Logs Sales Growth in Q1, but Profits Drop Sharply on Write-Offs
August 2, 2021
Xtandi Bullish, but Astellas Sales Wane 3.9% on Deal Wind-Ups; Profits Dip after Gene Therapy Trial Hold
April 28, 2021
Astellas’ 9-Month Earnings Stumble on Celecox Generic Erosion, Sales Pact Terminations
February 1, 2021
Astellas Earnings Flounder in April-September on LOEs, Deal Terminations
November 2, 2020
Astellas’ Q1 Sales Falter 8% on Deal Terminations, COVID-19
August 5, 2020
Astellas Sees New Drug Growth Counter Off-Patent Dip in FY2019
May 15, 2020

BUSINESS

Pharma Hails End to “Spillover” Rule, Vows to Keep Fighting Off-Year Cuts
December 25, 2025
Drug Wholesalers Slam “No-Discussion” Decision on FY2027 Off-Year Price Revision
December 25, 2025
JCR Earns Japan Rights to DMD Drug from Italfarmaco
December 25, 2025
Fujifilm Completes Major Biologics CDMO Plant in Toyama, Eyes 2027 Start-Up
December 25, 2025
Alfresa’s Cell Resources Inks Partnership with Korea’s ENCell
December 25, 2025

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests

By Takashi Ebisawa

The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…

COMMENTARY

Radioligand Therapy Faces Capacity Bottleneck in Japan, System Build-Out Needed to Deliver on Promise

By Koji Shimomura

Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…